Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors

Cell Growth and Differentiation

Volumn 11, Issue 5, 2000, Pages 239-246

  Chen, Feng ^a   Chang, Daniel ^a   Goh, Meidee ^b   Klibanov, Sergey A ^a   Ljungman, Mats ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL NUCLEUS; COLON CANCER; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SKIN FIBROBLAST; TUMOR SUPPRESSOR GENE;

ACETYLCYSTEINE; APOPTOSIS; CELL NUCLEUS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; FIBROBLASTS; G1 PHASE; G2 PHASE; HUMANS; INTERPHASE; MITOSIS; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; SKIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034041823     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Varshavsky, A. The ubiquitin system. Trends Biochem. Sci., 22: 383-387, 1997.
2. Hilt, W., and Wolf, D. H. Proteasomes: destruction as a programme. Trends Biochem. Sci., 21: 96-102, 1996.
3. Koepp, D., Harper, J., and Elledge, S. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell, 97: 431-434, 1999.
4. Chowdary, D., Dermody, J., Jha, K., and Ozer, H. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol., 14: 1997-2003, 1994.
5. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res., 56: 2649-2654, 1996.
6. Brown, J., and Pagano, M. Mechanism of p53 degradation. Biochim. Biophys. Acta, 1332: 1-6, 1997.
7. Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia, 2: 208-225, 2000.
8. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
9. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
10. Honda, R., Tanaka, H., and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420: 25-27, 1997.
11. Fuchs, S. Y., Adler, V., Buschmann, T., Yin, Z. M., Wu, X. W., Jones, S. N., and Ronai, Z. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev., 12: 2658-2663, 1998.
12. Freedman, D. A., and Levine, A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol., 18: 7288-7293, 1998.
13. Tao, W. K., and Levine, A. J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA, 96: 3077-3080, 1999.
14. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J., 18: 1660-1672, 1999.
15. Maltzman, W., and Czyzyk, L. UV irradiation stimulates levels of p53 cellular antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689-1694, 1984.
16. Kastan, M., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
17. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. DMA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 97: 325-334, 1997.
18. Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., and Kastan, M. B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev., 11: 3471-3481, 1997.
19. Shieh, S. Y., Taya, Y., and Prives, C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J., 18: 1815-1823, 1999.
20. Unger, T., Juven-Gershon, T., Moallem, E., Berger, M., Sionov, R. V., Lozano, G., Oren, M., and Haupt, Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J., 18: 1805-1814, 1999.
21. Mayo, L. D., Turchi, J. J., and Berberich, S. J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res., 57: 5013-5016, 1997.
22. Zhang, Y. P., and Xiong, Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell, 3: 579-591, 1999.
23. Ljungman, M., Zhang, F. F., Chen, F., Rainbow, A. J., and McKay, B. C. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene, 18: 583-592, 1999.
24. Gazos Lopes, U., Erhardt, P., Yao, R., and Cooper, G. p53-dependent induction of apoptosis by proteosome inhibitors. J. Biol. Chem., 272: 12893-12896, 1997.
25. Chang, Y. C., Lee, Y. S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ., 9: 79-84, 1998.
26. Shinohara, K., Tomioka, M., Nakano, H., Tone, S., Ito, H., and Kawashima, S. Apoptosis induction resulting from proteasome inhibition. Biochem. J., 317: 385-388, 1996.
27. Drexler, H. C. A. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA, 94: 855-860, 1997.
28. Lain, S., Midgley, C., Sparks, A., Lane, E. B., and Lane, D. P. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell. Res., 248: 457-472, 1999.
29. Maki, C. G., and Howley, P. M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol., 17: 355-363, 1997.
30. Herrmann, J. L., Briones, F., Jr., Brisbay, S., Logothetis, C. J., and McDonnell, T. J. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17: 2889-2899, 1998.
31. An, B., Goldfarb, R., Siman, R., and Dou, P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ., 5: 1062-1075, 1998.
32. Magae, J., Illenye, S., Tejima, T., Chang, Y. C., Mitsui, Y., Tanaka, K., Omura, S., and Heintz, N. H. Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin. Oncogene, 15: 759-769, 1997.
33. Rock, K., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78: 761-771, 1994.
34. Fenteany, G., Standaert, R., Lane, W., Choi, S., Corey, E., and Schreiber, S. Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science (Washington DC), 268: 726-731, 1995.
35. Scheffner, M., Werness, B., Huibregtse, J., Levine, A., and Howley, P. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
36. Scheffner, M., Huibregtse, J. M., and Howley, P. M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA, 91: 8797-8801, 1994.
37. Smith, M. L., Chen, I. T., Zhan, Q. M., Oconnor, P. M., and Fornace, A. J. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene, 10: 1053-1059, 1995.
38. Chang, D., Chen, F., Zhang, F. F., McKay, B. C., and Ljungman, M. Dose-dependent effects of DMA-damaging agents on p53-mediated cell cycle arrest. Cell Growth Differ., 10: 155-162, 1999.
39. 1 arrest in UV-irradiated human skin fibroblasts. Cancer Res., 57: 3390-3394, 1997.
40. Liang, S. H., Hong, D., and Clarke, M. F. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J. Biol. Chem., 273: 19817-19821, 1998.
41. El-Deiry, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J., Lin, D., Mercer, W., Kinzler, K., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
42. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 12: 2831-2841, 1998.
43. Lambert, P. F., Kashanchi, F., Radonovich, M. F., Shiekhattar, R., and Brady, J. N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem., 273: 33048-33053, 1998.
44. Dietrich, C., Bartsch, T., Schanz, F., Oesch, F., and Wieser, R. J. p53-dependent cell cycle arrest induced by W-acetyl-L-leucinyl-L-leucinyl-L-norteucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. USA, 93: 10815-10819, 1996.
45. Diehl, J., Zindy, F., and Sherr, C. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteosome pathway. Genes Dev., 11: 957-972, 1997.
46. Hofmann, F., Martelli, F., Livingston, D., and Wang, Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteosome pathway. Genes Dev., 10: 2949-2959, 1996.
47. Guillouf, C., Rosselli, F., Krishnaraju, K., Moustacchi, E., Hoffman, B., and Liebermann, D. A. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene, 10: 2263-2270, 1995.
48. Grimm, L. M., Goldberg, A. L., Poirier, G. G., Schwartz, L. M., and Osbome, B. A. Proteasomes play an essential role in thymocyte apoptosis. EMBO J., 15: 3835-3844, 1996.
49. Sadoul, R., Fernandez, P. A., Quiquerez, A. L., Martinou, I., Maki, M., Schroter, M., Becherer, J. D., Irmler, M., Tschopp, J., and Martinou, J. C. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J., 15: 3845-3852, 1996.
50. Adams, J., Palombella, V., Sausville, E., Johnson, J., Destree, A., Lazarus, D., Maas, J., Pien, C., Prakash, S., and Elliott, P. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59: 2615-2622, 1999.
51. Meng, L., Kwok, B., Sin, N., and Crews, C. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res., 59: 2798-2801, 1999.
52. Kuerbitz, S., Plunkett, B., Walsh, V., and Kastan, M. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
53. Kessis, T., Slebos, R., Nelson, W., Kastan, M., Plunkett, B., Han, S., Lorincz, A., Hedrick, L., and Cho, K. Human papillomavirus 16 E6 expression disrupts p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
54. Ljungman, M., and Zhang, F. Blockage of RNA polymerase as a possible trigger for uv light-induced apoptosis. Oncogene, 13: 823-831, 1996.
55. Hoy, C., Seamer, L., and Schimke, R. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. Cytometry, 10: 718-725, 1989.
56. Chung, D. H., Zhang, F. F., Chen, F., McLaughlin, W. P., and Ljungman, M. Butyrate attenuates BCLXL expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis. Radiat. Res., 149: 187-194, 1998.